Press release
Investigation announced for Long-Term Investors in ImmunityBio, Inc. (NASDAQ: IBRX) shares
An investigation on behalf of current long term investors in ImmunityBio, Inc. (NASDAQ: IBRX) shares.
Investors who are current long term investors in ImmunityBio, Inc. (NASDAQ: IBRX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: IBRX stocks follows a lawsuit filed against ImmunityBio, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: IBRX stocks, concerns whether certain ImmunityBio, Inc. directors are liable in connection with the allegations made in that lawsuit.
San Diego, CA based ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. ImmunityBio, Inc. (NASDAQ: IBRX) reported that its annual Total Revenue rose from $14.75 million in 2024 to over $113.28 million in 2025 and that its Net Loss declined from $303.35 million in 2024 to $282.76 million in 2025.
On March 24, 2026, Bloomberg reported that ImmunityBio had receive a Warning Letter from the U.S. Food and Drug Administration ("FDA") stating that the Company's Executive Chairman and Global Chief Scientific and Medical Officer, Patrick Soon-Shiong, made inaccurate claims on a podcast regarding the Company's lead biologic product, Anktiva, including that the drug "can cure and even prevent all cancer." The FDA thus "determined that the TV ad and podcast are false or misleading" and "make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act."
Shares of ImmunityBio, Inc. (NASDAQ: IBRX) declined from $12.43 per share on February 25, 2026, to as low as $6.54 per share on March 24, 2026.
According to that complaint filed in the U.S. District Court for the Central District of California the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that the defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities, and that as a result, defendants' statements about ImmunityBio's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased shares of ImmunityBio, Inc. (NASDAQ: IBRX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in ImmunityBio, Inc. (NASDAQ: IBRX) shares here
News-ID: 4573410 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit Alert: Investors who lost money with Hub Group, Inc. (NASDAQ: HUBG) shou …
An investor, who purchased shares of Hub Group, Inc. (NASDAQ: HUBG), filed a lawsuit over alleged violations of Federal Securities Laws by Hub Group, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Hub Group, Inc. (NASDAQ: HUBG) have certain options and for certain investors are short and strict deadlines running. Deadline: August 28, 2026. NASDAQ: HUBG investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lucid Group, Inc. (NASDAQ: LCID) Investor Alert: Deadline in Lawsuit on July 28, …
A deadline is coming up on July 28, 2026 in the lawsuit filed for certain investors of Lucid Group, Inc. (NASDAQ: LCID) over alleged securities laws violations by Lucid Group, Inc.
Investors who purchased shares of Lucid Group, Inc. (NASDAQ: LCID) have certain options and there are strict and short deadlines running. Deadline: July 28, 2026. Lucid Group, Inc. (NASDAQ: LCID) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Investigation Alert: Long-Term Investors who hold shares of Vital Farms, Inc. (N …
An investigation was announced for current long-term investors in shares of Vital Farms, Inc. (NASDAQ: VITL) concerning potential breaches of fiduciary duties by certain directors of Vital Farms, Inc.
Investors who are current long term investors in Vital Farms, Inc. (NASDAQ: VITL) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
ALERT: Lawsuit filed for Investors who lost money with shares of First Solar, In …
An investor, who purchased shares of First Solar, Inc. (NASDAQ: FSLR), filed a lawsuit over alleged violations of Federal Securities Laws by First Solar, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of First Solar, Inc. (NASDAQ: FSLR) have certain options and for certain investors are short and strict deadlines running. Deadline: August 24, 2026. NASDAQ: FSLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for ImmunityBio
Lawsuit Alert: Investors who lost money with shares of ImmunityBio, Inc. (NASDAQ …
An investor, who purchased shares of ImmunityBio, Inc. (NASDAQ: IBRX), filed a lawsuit over alleged violations of Federal Securities Laws by ImmunityBio, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of ImmunityBio, Inc. (NASDAQ: IBRX) have certain options and for certain investors are short and strict deadlines running. Deadline: May 26, 2026. NASDAQ: IBRX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Nk Cell Therapy Clinical Trials, Companies, Therapeutic Assessment, Therapies, T …
DelveInsight's, "NK Cell Therapies Pipeline Insight, 2025" report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Nk Cell Therapy Pipeline constitutes 140+ key companies continuously…
Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States …
The Key Natural Killer (NK)-Cell Lymphoma Companies in the market include - Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity, and others.
DelveInsight's "Natural Killer (NK)-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Natural Killer (NK)-Cell Lymphoma, historical and forecasted epidemiology as well as the Natural Killer (NK)-Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To…
NK Cell Therapy Pipeline Outlook Report 2024 (Updated) | ImmunityBio, Cantargia, …
DelveInsight's, "NK Cell Therapy Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key…
Bladder Cancer Pipeline Outlook Report 2024 | CG Oncology, ImmunityBio, UroGen, …
DelveInsight's, "Bladder Cancer Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
Investigation announced for Long-Term Investors in shares of ImmunityBio, Inc. ( …
An investigation was announced for current long-term investors in shares of ImmunityBio, Inc. (NASDAQ: IBRX) concerning potential breaches of fiduciary duties by certain directors of ImmunityBio, Inc.
Investors who are current long term investors in ImmunityBio, Inc. (NASDAQ: IBRX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors NASDAQ: IBRX stocks follows…
